Hesperidin identified from Citrus extracts potently inhibits HCV genotype 3a NS3 protease

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2662-7671

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Hesperidin identified from Citrus extracts potently inhibits HCV genotype 3a NS3 protease ; volume:22 ; number:1 ; day:2 ; month:4 ; year:2022 ; pages:1-18 ; date:12.2022
BMC complementary medicine and therapies ; 22, Heft 1 (2.4.2022), 1-18, 12.2022

Creator: Khan, Mahim
Rauf, Waqar
Habib, Fazal-e-
Rahman, Moazur
Iqbal, Shoaib
Shehzad, Aamir
Iqbal, Mazhar

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12906-022-03578-1

URN: urn:nbn:de:101:1-2022062120224667536887

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:30 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Khan, Mahim
Rauf, Waqar
Habib, Fazal-e-
Rahman, Moazur
Iqbal, Shoaib
Shehzad, Aamir
Iqbal, Mazhar
SpringerLink (Online service)

Other Objects (12)

Hochschulschrift

Untersuchungen zur Kooperation funktioneller Module in der NS2-NS3- und NS3-NS4A-Protease des Hepatitis-C-Virus (HCV)

Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors

Resistance analyses of HCV NS3/4A protease and NS5B polymerase from clinical studies of deleobuvir and faldaprevir

Investigation of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy

Evaluation of the immunogenicity of liposome encapsulated HVR1 and NS3 regions of genotype 3 HCV, either singly or in combination

Molecular iInsights into protease inhibition: design and interactions of NS2B-NS3 protease inhibitors

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment

Molecular models of NS3 protease variants of the Hepatitis C virus

Synthesis of HCV Protease Inhibitor MK-6325

HCV genotype-specific correlation with serum markers: Higher predictability for genotype 4a

Hochschulschrift

Untersuchungen zur Kooperation funktioneller Module in der NS2-NS3- und NS3-NS4A-Protease des Hepatitis-C-Virus (HCV)

Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors

Resistance analyses of HCV NS3/4A protease and NS5B polymerase from clinical studies of deleobuvir and faldaprevir

Investigation of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy

Evaluation of the immunogenicity of liposome encapsulated HVR1 and NS3 regions of genotype 3 HCV, either singly or in combination

Molecular iInsights into protease inhibition: design and interactions of NS2B-NS3 protease inhibitors

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment

Molecular models of NS3 protease variants of the Hepatitis C virus

Synthesis of HCV Protease Inhibitor MK-6325

HCV genotype-specific correlation with serum markers: Higher predictability for genotype 4a

Hochschulschrift

Untersuchungen zur Kooperation funktioneller Module in der NS2-NS3- und NS3-NS4A-Protease des Hepatitis-C-Virus (HCV)

Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors

Resistance analyses of HCV NS3/4A protease and NS5B polymerase from clinical studies of deleobuvir and faldaprevir

Investigation of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy

Evaluation of the immunogenicity of liposome encapsulated HVR1 and NS3 regions of genotype 3 HCV, either singly or in combination

Molecular iInsights into protease inhibition: design and interactions of NS2B-NS3 protease inhibitors

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment

Molecular models of NS3 protease variants of the Hepatitis C virus

Synthesis of HCV Protease Inhibitor MK-6325

HCV genotype-specific correlation with serum markers: Higher predictability for genotype 4a

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Hesperidin identified from Citrus extracts potently inhibits HCV genotype 3a NS3 protease

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Untersuchungen zur Kooperation funktioneller Module in der NS2-NS3- und NS3-NS4A-Protease des Hepatitis-C-Virus (HCV)

Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors

Resistance analyses of HCV NS3/4A protease and NS5B polymerase from clinical studies of deleobuvir and faldaprevir

Investigation of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy

Evaluation of the immunogenicity of liposome encapsulated HVR1 and NS3 regions of genotype 3 HCV, either singly or in combination

Molecular iInsights into protease inhibition: design and interactions of NS2B-NS3 protease inhibitors

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment

Molecular models of NS3 protease variants of the Hepatitis C virus

Synthesis of HCV Protease Inhibitor MK-6325

HCV genotype-specific correlation with serum markers: Higher predictability for genotype 4a

Untersuchungen zur Kooperation funktioneller Module in der NS2-NS3- und NS3-NS4A-Protease des Hepatitis-C-Virus (HCV)

Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors

Resistance analyses of HCV NS3/4A protease and NS5B polymerase from clinical studies of deleobuvir and faldaprevir

Investigation of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy

Evaluation of the immunogenicity of liposome encapsulated HVR1 and NS3 regions of genotype 3 HCV, either singly or in combination

Molecular iInsights into protease inhibition: design and interactions of NS2B-NS3 protease inhibitors

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment

Molecular models of NS3 protease variants of the Hepatitis C virus

Synthesis of HCV Protease Inhibitor MK-6325

HCV genotype-specific correlation with serum markers: Higher predictability for genotype 4a

Untersuchungen zur Kooperation funktioneller Module in der NS2-NS3- und NS3-NS4A-Protease des Hepatitis-C-Virus (HCV)

Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors

Resistance analyses of HCV NS3/4A protease and NS5B polymerase from clinical studies of deleobuvir and faldaprevir

Investigation of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy

Evaluation of the immunogenicity of liposome encapsulated HVR1 and NS3 regions of genotype 3 HCV, either singly or in combination

Molecular iInsights into protease inhibition: design and interactions of NS2B-NS3 protease inhibitors

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment

Molecular models of NS3 protease variants of the Hepatitis C virus

Synthesis of HCV Protease Inhibitor MK-6325

HCV genotype-specific correlation with serum markers: Higher predictability for genotype 4a

Related objects

Reset password